| Literature DB >> 29069483 |
Amandine Anastácio1,2, Kenny A Rodriguez-Wallberg2,3, Solenne Chardonnet4, Cédric Pionneau4, Christian Fédérici5, Teresa Almeida Santos6,7, Catherine Poirot1,8.
Abstract
STUDY QUESTION: Could the follicle proteome be mapped by identifying specific proteins that are common or differ between three developmental stages from the secondary follicle (SF) to the antrum-like stage? SUMMARY ANSWER: From a total of 1401 proteins identified in the follicles, 609 were common to the three developmental stages investigated and 444 were found uniquely at one of the stages. WHAT IS KNOWN ALREADY: The importance of the follicle as a functional structure has been recognized; however, up-to-date the proteome of the whole follicle has not been described. A few studies using proteomics have previously reported on either isolated fully-grown oocytes before or after meiosis resumption or cumulus cells. STUDY DESIGN, SIZE, DURATION: The experimental design included a validated mice model for isolation and individual culture of SFs. The system was chosen as it allows continuous evaluation of follicle growth and selection of follicles for analysis at pre-determined developmental stages: SF, complete Slavjanski membrane rupture (SMR) and antrum-like cavity (AF). The experiments were repeated 13 times independently to acquire the material that was analyzed by proteomics. PARTICIPANTS/MATERIALS, SETTING,Entities:
Keywords: follicle development; in vitro growth; mouse; ovarian follicle; proteomics
Mesh:
Substances:
Year: 2017 PMID: 29069483 PMCID: PMC5909860 DOI: 10.1093/molehr/gax056
Source DB: PubMed Journal: Mol Hum Reprod ISSN: 1360-9947 Impact factor: 4.025
Figure 1Schematic chart indicating (a) Type and numbers of animals used in the study and numbers of secondary follicles (SFs) that were isolated and cultured in repeated independent experiments. From culture, follicles were collected when Slavjsanki Membrane Rupture (SMR) was observed or antrum-like cavity (AF). Morphological characteristics of the follicles selected at each stage are illustrated indicating: size, visible oocyte (O), granulosa cells (GC) theca cells (TC) and the presence of antrum (black arrow). The quantity of pooled protein obtained from selected follicles at each stage is also indicated. (b) Schematic description of how the total protein extract (TPE) from each follicle stage was fractionated by isoelectric focusing (IEF) with stacking in SDS-PAGE gel and manual band excision for digestion.
Figure 2Fractionation was performed to increase the likelihood of obtaining a higher number of identified proteins in the samples. The figure illustrates this by showing: (a) the number of proteins identified in AF stage analyzing either only TPE or only the Fractions, and the combination of both; (b) the percentage of proteins identified in one single fraction, or in 2, 3, 4 or 5 fractions and (c) a Venn diagram of proteins identified in ovarian follicles. The blue circle contains proteins identified at the SF stage; the green circle contains proteins identified at the SMR stage; and the purple circle contains proteins identified at the AF stage.
Figure 3Venn diagram comparing the mouse follicle proteome found in this study and the proteome of metaphase II oocytes (MII) (Ma ; Zhang ; Wang ; Pfeiffer ), germinal vesicle oocytes (GV) (Wang ; Demant ) and cumulus-oocyte complex (COC) (Meng ).
Figure 4Gene Ontology (GO) analysis of the proteins identified at the three stages. (a) Distribution of the proteins identified for each group according to PANTHER protein class. (b) Functional classification based on Biological Processes. *Signifies biological process over-represented in samples when compared to the whole mouse genome.
Figure 5Follicle proteins identified related to (a) DNA repair and (b) ROS generation. The images were generated by Pathway Studio. Proteins identified are shown using white background and non-identified using color background.
Figure 6CDKs and related protein interactions underlined by Ingenuity Pathway Analysis (IPA). Proteins in gray were detected in the samples, and those in white were not. This network showed 12 proteins whose expressions were different between the three stages: (a) SF stage, (b) SMR stage and (c) AF stage. Proteins surrounded in green indicate they were identified at that stage; proteins surrounded in red were not identified.
Proteins differently expressed in the three stages.
| Accession number | Protein name | Gene name | Protein score | ANOVA | Fold-change | Max. | Min. | Profile Type (Fig. |
|---|---|---|---|---|---|---|---|---|
| Q8K3V4 | Protein-arginine deiminase type-6 | Padi6 | 1103.2 | 1.9E-07 | 3.6 | SF | AF | P1 |
| P16125 | L-lactate dehydrogenase B chain | Ldhb | 879.7 | 7.0E-06 | 4.9 | SF | AF | P1 |
| F8WIV2 | Protein Serpinb6a | Serpinb6a | 648.1 | 3.4E-07 | 2.4 | SF | AF | P1 |
| Q9CWU5 | KH domain-containing protein 3 | Khdc3 | 569.8 | 5.9E-05 | 3.2 | SF | SMR/AF | P1 |
| Q9R0P9 | Ubiquitin carboxyl-terminal hydrolase isozyme L1 | Uchl1 | 509.7 | 6.9E-05 | 4.4 | SF | AF | P1 |
| P24549 | Retinal dehydrogenase 1 | Aldh1a1 | 418.6 | 8.0E-04 | 2.0 | SF | SMR | P1 |
| P10761 | Zona pellucida sperm-binding protein 3 | Zp3 | 346.3 | 7.2E-05 | 4.9 | SF | AF | P1 |
| P54869 | Hydroxymethylglutaryl-CoA synthase, mitochondrial | Hmgcs2 | 335.2 | 1.0E-02 | 2.1 | SF | SMR | P1 |
| Q9DAW9 | Calponin-3 | Cnn3 | 308.2 | 2.3E-04 | 2.5 | SF | AF | P1 |
| Q9WVB3 | Transducin-like enhancer protein 6 | Tle6 | 239.0 | 1.9E-06 | 3.5 | SF | AF | P1 |
| P10518 | Delta-aminolevulinic acid dehydratase | Alad | 230.6 | 2.0E-04 | 2.7 | SF | AF | P1 |
| P20239 | Zona pellucida sperm-binding protein 2 | Zp2 | 189.8 | 7.0E-05 | 2.6 | SF | AF | P1 |
| Q08EC7 | Pla2g4c protein | Pla2g4c | 188.0 | 2.4E-04 | 3.1 | SF | AF | P1 |
| P24472 | Glutathione S-transferase A4 | Gsta4 | 153.6 | 3.3E-04 | 2.7 | SF | SMR | P1 |
| Q9CWE6 | Oocyte-expressed protein homolog | Ooep | 94.9 | 2.0E-02 | 4.8 | SF | SMR/AF | P1 |
| P14211 | Calreticulin | Calr | 276.5 | 1.3E-05 | 4.6 | SMR | SF | P2 |
| Q60817 | Nascent polypeptide-associated complex subunit alpha | Naca | 270.9 | 1.6E-04 | 2.3 | SMR | AF | P2 |
| Q60605 | Myosin light polypeptide 6 | Myl6 | 174.3 | 1.6E-03 | 3.4 | SMR | SF/AF | P2 |
| G3UWR0 | Calumenin | Calu | 161.2 | 5.1E-05 | 3.1 | SMR | SF | P2 |
| Q4VAA2 | Protein CDV3 | Cdv3 | 106.5 | 2.1E-04 | 2.5 | SMR | AF | P2 |
| P20029 | 78 kDa glucose-regulated protein | Hspa5 | 2951.4 | 2.6E-05 | 2.7 | AF | SF | P3 |
| P17182 | Alpha-enolase | Eno1 | 1548.7 | 4.5E-07 | 5.0 | AF | SF | P3 |
| P05213 | Tubulin alpha-1B chain | Tuba1b | 1527.4 | 7.0E-04 | 2.7 | AF | SF | P3 |
| P09103 | Protein disulfide-isomerase | P4hb | 1416.4 | 4.3E-06 | 2.7 | AF | SF | P3 |
| P16858 | Glyceraldehyde-3-phosphate dehydrogenase | Gapdh | 701.4 | 1.6E-07 | 4.0 | AF | SF | P3 |
| P14152 | Malate dehydrogenase, cytoplasmic | Mdh1 | 462.0 | 4.8E-06 | 2.1 | AF | SF | P3 |
| P48036 | Annexin A5 | Anxa5 | 445.8 | 5.5E-04 | 2.0 | AF | SF | P3 |
| Q99KV1 | DnaJ homolog subfamily B member 11 | Dnajb11 | 420.4 | 1.1E-03 | 2.2 | AF | SF | P3 |
| G5E8N5 | L-lactate dehydrogenase | Ldha | 412.5 | 3.1E-06 | 3.4 | AF | SF | P3 |
| P24815 | 3 beta-hydroxysteroid dehydrogenase/Delta 5-- > 4-isomerase type 1 | Hsd3b1 | 394.6 | 6.4E-03 | 3.1 | AF | SF | P3 |
| E9PXX7 | Thioredoxin domain-containing protein 5 | Txndc5 | 380.2 | 4.7E-03 | 2.1 | AF | SF | P3 |
| P57759 | Endoplasmic reticulum resident protein 29 | Erp29 | 361.6 | 3.1E-05 | 2.5 | AF | SF | P3 |
| O08807 | Peroxiredoxin-4 | Prdx4 | 358.2 | 4.0E-05 | 2.2 | AF | SF | P3 |
| P29758 | Ornithine aminotransferase, mitochondrial | Oat | 354.1 | 5.3E-04 | 2.1 | AF | SF | P3 |
| P51656 | Estradiol 17-beta-dehydrogenase 1 | Hsd17b1 | 351.2 | 3.6E-03 | 2.4 | AF | SF | P3 |
| P53994 | Ras-related protein Rab-2A | Rab2a | 330.6 | 3.3E-03 | 2.0 | AF | SF | P3 |
| Q9DBJ1 | Phosphoglycerate mutase 1 | Pgam1 | 329.4 | 6.5E-04 | 2.2 | AF | SF | P3 |
| P17742 | Peptidyl-prolyl cis-trans isomerase A | Ppia | 325.5 | 5.8E-03 | 2.2 | SMR | SF | P3 |
| P09411 | Phosphoglycerate kinase 1 | Pgk1 | 300.5 | 2.8E-03 | 2.7 | AF | SF | P3 |
| Q60715 | Prolyl 4-hydroxylase subunit alpha-1 | P4ha1 | 271.1 | 7.0E-05 | 2.2 | AF | SF | P3 |
| Q9QXT0 | Protein canopy homolog 2 | Cnpy2 | 254.6 | 3.8E-03 | 2.3 | SMR | SF | P3 |
| A2A7Q5 | Prolyl 3-hydroxylase 1 | Lepre1 | 225.9 | 2.7E-03 | 2.3 | AF | SF | P3 |
| G5E850 | Cytochrome b-5, isoform CRA_a | Cyb5 | 222.6 | 4.9E-05 | 3.4 | AF | SF | P3 |
| Q3U4W8 | Ubiquitin carboxyl-terminal hydrolase | Usp5 | 216.6 | 5.5E-03 | 2.2 | AF | SF | P3 |
| G3XA14 | Protein Akr1cl | Akr1cl | 212.7 | 7.5E-03 | 3.4 | SMR | SF | P3 |
| P34884 | Macrophage migration inhibitory factor | Mif | 210.1 | 1.6E-05 | 2.1 | AF | SF | P3 |
| P22935 | Cellular retinoic acid-binding protein 2 | Crabp2 | 130.9 | 2.2E-04 | 2.6 | AF | SF | P3 |
| Q9CYA0 | Cysteine-rich with EGF-like domain protein 2 | Creld2 | 107.5 | 2.0E-02 | 2.9 | AF | SF | P3 |
| P63158 | High-mobility group protein B1 | Hmgb1 | 267.9 | 2.0E-03 | 2.5 | SF | SMR | P4 |
| Q9JKB1 | Ubiquitin carboxyl-terminal hydrolase isozyme L3 | Uchl3 | 226.8 | 1.1E-03 | 2.6 | SF | SMR | P4 |
| Q9ERD7 | Tubulin beta-3 chain | Tubb3 | 1342.8 | 1.6E-03 | 3.3 | AF | SMR | P5 |
| P31324 | cAMP-dependent protein kinase type II-beta regulatory subunit | Prkar2b | 1129.2 | 1.7E-04 | 3.7 | AF | SF | P5 |
| Q05816 | Fatty acid-binding protein, epidermal | Fabp5 | 781.9 | 9.1E-05 | 3.1 | AF | SF | P5 |
| P17751 | Triosephosphate isomerase | Tpi1 | 627.6 | 5.7E-05 | 2.3 | AF | SF | P5 |
| Q9D0F9 | Phosphoglucomutase-1 | Pgm1 | 403.2 | 1.2E-04 | 2.3 | AF | SF/SMR | P5 |
| Q99JF5 | Diphosphomevalonate decarboxylase | Mvd | 161.0 | 9.7E-05 | 3.6 | AF | SF | P5 |
| Q62159 | Rho-related GTP-binding protein RhoC | Rhoc | 136.3 | 2.1E-04 | 2.4 | AF | SMR | P5 |
Fold-change and ANOVA were calculated between the maximal and the minimal abundance obtained for each protein. The protein score is the sum of Mascot scores of the identified peptides. Proteins were validated when at least two peptides were significant, with an ANOVA P-value 0.05 and a fold-change ≥2. Profile Type (P1–P5) refers to the normalized abundance behavior of the protein (see Fig. 7).
Figure 7Standardized Normalized Abundance profiles of proteins differently expressed between developmental stages. (P1) 15 proteins with highest abundance in SF stage. (P2) 5 proteins with maximal abundance at SMR stage. (P3) 28 proteins corresponding to increasing abundance throughout developmental stages. (P4) 2 proteins with a significant decrease at SMR stage compared to the other two stages. (P5) 7 proteins with a significant variation between the two first stages (SF and SMR) and the AF stage, which is the stage with the highest abundance.
Figure 8Abundance profile of proteins implicated in glycolysis, with a significant variation throughout follicle development in vitro. In red, eight proteins with increasing abundance during the stages. In blue, one protein, LDHB, with decreasing abundance during follicle development in vitro.
Figure 9Western blot demonstrating variable expression of PRKAR2B, LDHB and CDKN1B at the three stages. It is possible to observe an increasing expression of PRKAR2B and CDKN1B during the culture, with a higher expression in the two later stages of development. The decreasing expression of LDHB during follicle development is also shown by western blot, with similar abundance in the SMR and AF stages.